DK3472149T3 - Heterocykliske prolinamidderivater - Google Patents

Heterocykliske prolinamidderivater Download PDF

Info

Publication number
DK3472149T3
DK3472149T3 DK17815962.0T DK17815962T DK3472149T3 DK 3472149 T3 DK3472149 T3 DK 3472149T3 DK 17815962 T DK17815962 T DK 17815962T DK 3472149 T3 DK3472149 T3 DK 3472149T3
Authority
DK
Denmark
Prior art keywords
proline
heterocyclic
mid
derivatives
mid derivatives
Prior art date
Application number
DK17815962.0T
Other languages
English (en)
Inventor
Robert Gomez
Jinyue Ding
Renata Marcella Oballa
David Andrew Powell
Maxim Epifanov
Original Assignee
Orion Ophthalmology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Ophthalmology LLC filed Critical Orion Ophthalmology LLC
Application granted granted Critical
Publication of DK3472149T3 publication Critical patent/DK3472149T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
DK17815962.0T 2016-06-21 2017-06-15 Heterocykliske prolinamidderivater DK3472149T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662352963P 2016-06-21 2016-06-21
PCT/US2017/037768 WO2017222915A1 (en) 2016-06-21 2017-06-15 Heterocyclic prolinamide derivatives

Publications (1)

Publication Number Publication Date
DK3472149T3 true DK3472149T3 (da) 2023-11-27

Family

ID=60783554

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17815962.0T DK3472149T3 (da) 2016-06-21 2017-06-15 Heterocykliske prolinamidderivater

Country Status (21)

Country Link
US (2) US11377439B2 (da)
EP (2) EP3472149B1 (da)
JP (2) JP7179721B2 (da)
KR (2) KR102595723B1 (da)
CN (2) CN114685453A (da)
AU (2) AU2017282651B2 (da)
BR (1) BR112018076614A2 (da)
CA (1) CA3025253A1 (da)
DK (1) DK3472149T3 (da)
EA (1) EA201990069A1 (da)
ES (1) ES2971784T3 (da)
FI (1) FI3472149T3 (da)
HU (1) HUE064412T2 (da)
IL (1) IL263284B (da)
MX (1) MX2018016189A (da)
PH (1) PH12018502696A1 (da)
PL (1) PL3472149T3 (da)
PT (1) PT3472149T (da)
SG (1) SG11201810848PA (da)
UA (1) UA124672C2 (da)
WO (1) WO2017222915A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA124672C2 (uk) 2016-06-21 2021-10-27 Оріон Офтальмолоджі Ллс Гетероциклічні похідні пролінаміду
JP7164521B2 (ja) * 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5023236A (en) 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
US5225402A (en) 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
EP0732399A3 (en) 1990-03-05 1997-03-12 Cephalon Inc Chymotrypsin-like proteases and their inhibitors
GB9017694D0 (en) 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
GB9024129D0 (en) 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
US5712267A (en) 1991-06-04 1998-01-27 Sankyo Company,. Limited Carbapenem derivatives, their preparation and their use as antibiotics
JP2668003B2 (ja) 1992-06-12 1997-10-27 ファイザー インク． ヒトの心臓キマーゼを含むアンギオテンシンｉキマーゼに関する阻害剤
US5208313A (en) 1992-07-16 1993-05-04 Surface Coatings, Inc. Waterproof breathable polyurethane membranes and porous substrates protected therewith
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
IL109319A0 (en) 1993-04-27 1994-07-31 Du Pont Merck Pharma Amidino and guanidino substituted boronic acid compounds
AU670381B2 (en) 1993-04-30 1996-07-11 Merck & Co., Inc. Thrombin inhibitors
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
ES2170104T3 (es) 1993-10-01 2002-08-01 Merrell Pharma Inc Inhibidores de la produccion de proteinas de beta-amiloide.
IL111175A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
IL111176A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
GB9401483D0 (en) 1994-01-26 1994-03-23 Sandoz Ltd Organic compounds
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
WO1996016079A2 (en) 1994-11-24 1996-05-30 Takeda Chemical Industries, Ltd Alpha-ketoamide derivatives as cathepsin l inhibitor
US5919765A (en) 1995-06-07 1999-07-06 Cor Therapeutics, Inc. Inhibitors of factor XA
IL120310A (en) 1996-03-01 2002-02-10 Akzo Nobel Nv Serine protease inhibitors and pharmaceuticals containing them
TW523513B (en) 1996-03-01 2003-03-11 Akzo Nobel Nv Serine protease inhibitors
EP2314598A1 (en) 1996-10-18 2011-04-27 Vertex Pharmaceuticals Incorporated Inhibitors of Hepatitis C virus NS3 serine protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
HUP0100100A3 (en) 1997-08-11 2001-12-28 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide analogues, pharmaceutical compositions comprising thereof and their use
DE19746468A1 (de) 1997-10-21 1999-04-22 Henkel Kgaa Haar-Masara
WO2000008134A2 (en) 1998-08-03 2000-02-17 Novartis Ag HUMAN HtrA SERINE PROTEASE
WO2001006262A1 (en) 1999-02-19 2001-01-25 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration
WO2001002601A2 (en) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
WO2002006280A2 (en) 2000-07-13 2002-01-24 Millennium Pharamaceuticals, Inc. INHIBITORS OF FACTOR Xa
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7012066B2 (en) * 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
CN1446201A (zh) 2000-07-21 2003-10-01 先灵公司 用作丙型肝炎病毒ns3－丝氨酸蛋白酶抑制剂的新型肽
WO2002018335A1 (fr) 2000-08-28 2002-03-07 Yamanouchi Pharmaceutical Co., Ltd. Derives d'amine cyclique
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
FR2816509B1 (fr) 2000-11-15 2004-02-06 Sod Conseils Rech Applic Association d'inhibiteurs de calpaine et de piegeurs des formes reactives de l'oxygene
US7172874B2 (en) 2001-04-30 2007-02-06 The Cleveland Clinic Foundation Diagnostic methods for age related macular degeneration
US7244815B2 (en) 2001-05-23 2007-07-17 The Curators Of The University Of Missouri Attachment and elaboration strategies for inverse peptide synthesis
US7214769B2 (en) 2001-05-23 2007-05-08 The Curators Of The University Of Missouri Method for inverse solid phase synthesis of peptides
PT1399468E (pt) 2001-05-30 2006-05-31 Novartis Ag Derivados do acido 2-{[n-(2-amino-3-(heteroaril ou aril)propionil)-aminoacil]-amino}-alquilboronico
NZ561851A (en) 2002-04-11 2009-05-31 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
JP4312718B2 (ja) 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
CA2491466A1 (en) 2002-07-09 2004-01-15 Sharlene Adams Methods and compositions relating to isoleucine boroproline compounds
US20050282757A1 (en) 2002-09-09 2005-12-22 Trigen Limited Peptide boronic acid compounds useful in anticoagulation
US20050176651A1 (en) 2002-09-09 2005-08-11 Trigen Limited Peptide boronic acids useful in making salts thereof
MXPA05002662A (es) 2002-09-09 2005-09-20 Trigen Ltd Sales de metal multivalente de acidos boronicos para el tratamiento de trombosis.
US20050119226A1 (en) 2003-09-09 2005-06-02 Trigen Limited Methods for synthesizing organoboronic compounds and products thereof
EP2295402B1 (en) 2003-01-08 2015-08-12 The University of Washington Antibacterial agents
WO2004089297A2 (en) 2003-04-02 2004-10-21 Suntory Pharmaceutical Research Laboratories, Llc Compounds and methods for treatment of thrombosis
CN100453553C (zh) 2003-04-11 2009-01-21 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
WO2004113365A2 (en) * 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7273851B2 (en) 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors
CN1852920B (zh) 2003-07-18 2010-12-15 沃泰克斯药物股份有限公司 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
PE20050374A1 (es) 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
WO2005028502A1 (en) 2003-09-18 2005-03-31 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7365092B2 (en) 2003-10-10 2008-04-29 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
JP2007519744A (ja) 2004-01-30 2007-07-19 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト システインプロテアーゼインヒビターとしてのシリナン化合物。
JP2008505849A (ja) 2004-02-04 2008-02-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特に、ｈｃｖ、ｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
JP4781347B2 (ja) 2004-02-23 2011-09-28 トラスティーズ オブ タフツ カレッジ グルコース代謝を制御するためのペプチジルペプチダーゼｉｖ阻害剤
GB0405267D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
GB0405272D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
GB0405280D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
JP5053836B2 (ja) 2004-04-30 2012-10-24 テラプトシス エス アー カスパーゼ−２阻害剤およびそれらの生物学的適用
US7244851B2 (en) 2004-07-02 2007-07-17 Genentech, Inc. Inhibitors of IAP
FR2873695A1 (fr) 2004-07-30 2006-02-03 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un antibiotique ou un inhibiteur de resistance), leur synthese et leurs utilisations en tant qu'agent antibacterien
US20080058324A1 (en) 2004-08-25 2008-03-06 Santhera Pharmaceuticals (Schweiz) Ag Alpha-Keto Carbonyl Calpain Inhibitors
CA2578006A1 (en) 2004-08-25 2006-03-02 Santhera Pharmaceuticals (Schweiz) Ag Alpha-keto carbonyl calpain inhibitors
WO2006059082A1 (en) 2004-11-30 2006-06-08 Trigen Limited Oxidised lipids as reversal agents for boronic acid drugs
WO2006059083A1 (en) 2004-11-30 2006-06-08 Trigen Limited Neutralising agents for boronic acid drugs
CN103920142A (zh) * 2005-02-14 2014-07-16 爱荷华大学研究基金会 治疗和诊断年龄相关性黄斑变性的方法和试剂
ZA200707420B (en) * 2005-02-14 2009-04-29 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
WO2006113942A2 (en) 2005-04-20 2006-10-26 Schering Corporation Method of inhibiting cathepsin activity
US20060275366A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US20060276405A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis C
WO2006130553A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
US20060276407A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US20060276406A1 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
JP2009503084A (ja) 2005-08-01 2009-01-29 フェノミックス コーポレーション Ｃ型肝炎セリンプロテアーゼ阻害剤およびその使用
JP2009524681A (ja) * 2006-01-27 2009-07-02 フェノミックス コーポレーション Ｃ型肝炎ウイルスセリンプロテアーゼインヒビターおよびそのための使用
WO2007095250A2 (en) 2006-02-13 2007-08-23 The Cleveland Clinic Foundation Compositions and methods for inhibiting optic nerve damage
US20070212865A1 (en) 2006-03-08 2007-09-13 Craig Amrine Method for planarizing vias formed in a substrate
MX2008013119A (es) 2006-04-11 2008-10-21 Novartis Ag Inhibidores de hcv/vih y sus usos.
WO2007120595A2 (en) 2006-04-11 2007-10-25 Novartis Ag Amines for the treatment of hcv
TW200815481A (en) 2006-06-06 2008-04-01 Enanta Pharm Inc Acyclic oximyl hepatitis C protease inhibitors
WO2007146831A2 (en) 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
MX2009000909A (es) 2006-07-26 2009-02-04 Univ Yale Diagnostico y tratamiento de degeneracion macular relacionada con la edad.
US20100166743A1 (en) 2006-10-06 2010-07-01 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
US20100129358A1 (en) 2006-12-22 2010-05-27 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
WO2008086053A1 (en) 2007-01-03 2008-07-17 Virobay, Inc. Hcv inhibitors
WO2008089485A2 (en) 2007-01-19 2008-07-24 The Cleveland Clinic Foundation Carboxyethylpyrrole compounds and methods of their production
WO2008103299A2 (en) 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
EP2125113A2 (en) 2007-02-26 2009-12-02 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
US20100196935A1 (en) 2007-03-12 2010-08-05 Mayo Foundation For Medical Education And Research Treating pre-eclempsia and cardiovascular diseases
WO2008118848A1 (en) 2007-03-23 2008-10-02 Trustees Of Tufts College N-substituted peptidomimetic inhibitors of dipeptidylpeptidase iv
US20100074867A1 (en) 2007-03-23 2010-03-25 Schering Corporation Patent Department, K-6-1; 1990 P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
EP2185524A1 (en) 2007-05-10 2010-05-19 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
TW200911290A (en) 2007-07-02 2009-03-16 Alcon Res Ltd RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration
WO2009006473A2 (en) 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
KR20150010802A (ko) 2007-08-06 2015-01-28 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
WO2009046405A2 (en) 2007-10-05 2009-04-09 University Of Utah Research Foundation Antibodies to htra1 and methods of using the same
US7683636B2 (en) 2007-10-26 2010-03-23 Honeywell International Inc. Structure for capacitive balancing of integrated relative humidity sensor
WO2009059317A2 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
CA2707549A1 (en) 2007-12-03 2009-06-11 Itzik Harosh Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
US8193346B2 (en) 2007-12-06 2012-06-05 Enanta Pharmaceuticals, Inc. Process for making macrocyclic oximyl hepatitis C protease inhibitors
CA2713108A1 (en) 2008-02-07 2009-08-13 Virobay, Inc. Inhibitors of cathepsin b
US20110110857A1 (en) 2008-03-06 2011-05-12 Roberto Petracca Mutant forms of chlamydia htra
CN101638414B (zh) 2008-07-30 2014-01-08 江苏先声药物研究有限公司 肽硼酸及其酯类化合物、制备方法及其用途
CN102177152A (zh) 2008-08-11 2011-09-07 哈佛大学校长及研究员协会 用于抑制tRNA合成酶的卤夫酮(halofuginone)类似物和其用途
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
SI2540843T1 (sl) 2008-11-05 2014-10-30 Genentech, Inc. Genetski polimorfizmi in starostna degeneracija makule
WO2010132459A2 (en) 2009-05-11 2010-11-18 Cleveland Clinic Foundation Biomarkers for assessment of age-related macular degeneration
CN101928329B (zh) 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
US20110104154A1 (en) 2009-10-30 2011-05-05 Alcon Research, Ltd. Single nucleotide polymorphisms and genes associated with age-related macular degeneration
CN104530079B (zh) * 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
US9365612B2 (en) 2010-01-29 2016-06-14 United States Of America As Represented By The Secretary, Department Of Health And Human Services Caspase inhibitors
SG183843A1 (en) 2010-03-01 2012-10-30 Onyx Therapeutics Inc Compounds for immunoproteasome inhibition
WO2011146401A1 (en) 2010-05-17 2011-11-24 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2011156632A2 (en) 2010-06-09 2011-12-15 Georgetown University Compositions and methods of treatment for tumors in the nervous system
WO2012040242A1 (en) 2010-09-22 2012-03-29 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
WO2012078540A1 (en) 2010-12-08 2012-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulating immune cell activity using cytokine-induced src homology 2 and/or high temperature requirement a-1
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
RU2013145890A (ru) 2011-03-15 2015-04-20 Юниверсити Оф Юта Рисерч Фаундейшн Способы диагностики и лечения сосудисто-ассоциированной макулопатии и ее симптомов
CN102807607B (zh) 2011-07-22 2013-10-23 爱博新药研发(上海)有限公司 抑制丙肝病毒的稠环杂环类化合物、其中间体及其应用
EP4144354A1 (en) 2011-08-30 2023-03-08 Trustees Of Tufts College Fap-activated proteasome inhibitors for treating solid tumors
HUE039133T2 (hu) 2011-10-14 2018-12-28 Hoffmann La Roche Anti-HtrA1 antitestek és felhasználási módszerek
EP2768517A4 (en) 2011-10-17 2015-03-11 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8549645B2 (en) 2011-10-21 2013-10-01 Mcafee, Inc. System and method for detection of denial of service attacks
KR20140132367A (ko) 2012-02-16 2014-11-17 알큐엑스 파마슈티컬스, 인크. 선형 펩티드 항생제
WO2013149306A1 (en) 2012-04-05 2013-10-10 Prince Henry's Institute Of Medical Research Antibodies to htra3
US20150211065A1 (en) 2012-09-14 2015-07-30 University Of Utah Research Foundation Methods of predicting the development of amd based on chromosome 1 and chromosome 10
MX371093B (es) 2013-05-01 2020-01-16 Regulus Therapeutics Inc Compuestos de microarn y metodos para modular al mir-122.
CA2924527C (en) 2013-09-20 2022-07-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds for treating prostate cancer
US9943604B2 (en) 2013-09-20 2018-04-17 Ionis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
JP6337750B2 (ja) 2013-11-22 2018-06-06 小野薬品工業株式会社 化合物
US9981942B2 (en) 2013-12-20 2018-05-29 Laboratorios Del Dr. Esteve S.A. Piperidine derivatives having multimodal activity against pain
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016100555A1 (en) * 2014-12-18 2016-06-23 Inception 4, Inc. Boronic acid derivatives and uses thereof
JP6836996B2 (ja) 2015-02-25 2021-03-03 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新しいトリフルオロメチルプロパンアミド誘導体
FR3034709B1 (fr) 2015-04-09 2017-04-14 Michelin & Cie Pneumatique muni d'un dispositif electronique
EP3294718B1 (en) 2015-05-11 2020-04-29 H. Hoffnabb-La Roche Ag New difluoroketamide derivatives
US10421821B2 (en) 2015-10-30 2019-09-24 Genentech, Inc. Anti-HtrA1 antibodies and methods of use thereof
CN108699105A (zh) 2016-03-04 2018-10-23 豪夫迈·罗氏有限公司 作为htra1抑制剂的新型二氟酮酰胺衍生物
JP2019513698A (ja) 2016-03-04 2019-05-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｔｒａ１阻害剤としての新規なトリフルオロメチルプロパンアミド誘導体
UA123836C2 (uk) 2016-06-21 2021-06-09 Оріон Офтальмолоджі Ллс Аліфатичні похідні пролінаміду
UA124672C2 (uk) 2016-06-21 2021-10-27 Оріон Офтальмолоджі Ллс Гетероциклічні похідні пролінаміду
JP7164521B2 (ja) * 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
TW201803990A (zh) 2016-07-01 2018-02-01 赫孚孟拉羅股份公司 用於調節htra1表現之反股寡核苷酸
CN109415330A (zh) 2016-07-18 2019-03-01 豪夫迈·罗氏有限公司 作为htra1抑制剂的新型二氟酮酰胺衍生物
JP2019526564A (ja) 2016-08-23 2019-09-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｔｒａ１阻害剤としての新規なトリフルオロメチルプロパンアミド誘導体
WO2018036942A1 (en) 2016-08-23 2018-03-01 F. Hoffmann-La Roche Ag New difluoroketamide derivatives as htra1 inhibitors
WO2018206816A1 (en) 2017-05-12 2018-11-15 Universität Duisburg-Essen Tailored cyclodepsipeptides as potent non-covalent serine protease inhibitors

Also Published As

Publication number Publication date
MX2018016189A (es) 2019-06-10
EP4257191A2 (en) 2023-10-11
WO2017222915A1 (en) 2017-12-28
JP2023027074A (ja) 2023-03-01
PH12018502696A1 (en) 2019-11-04
PT3472149T (pt) 2023-11-23
HUE064412T2 (hu) 2024-03-28
IL263284B (en) 2021-05-31
US20220267306A1 (en) 2022-08-25
CA3025253A1 (en) 2017-12-28
EP4257191A3 (en) 2023-11-22
CN114685453A (zh) 2022-07-01
BR112018076614A2 (pt) 2019-04-02
JP7179721B2 (ja) 2022-11-29
EP3472149A4 (en) 2020-01-15
KR20230153504A (ko) 2023-11-06
PL3472149T3 (pl) 2024-02-12
KR20190011322A (ko) 2019-02-01
CN109476637B (zh) 2022-02-01
ES2971784T3 (es) 2024-06-07
EA201990069A1 (ru) 2019-06-28
AU2017282651B2 (en) 2021-08-12
CN109476637A (zh) 2019-03-15
US20190322645A1 (en) 2019-10-24
IL263284A (en) 2018-12-31
EP3472149B1 (en) 2023-08-30
SG11201810848PA (en) 2019-01-30
EP3472149A1 (en) 2019-04-24
KR102595723B1 (ko) 2023-10-27
US11377439B2 (en) 2022-07-05
FI3472149T3 (fi) 2023-11-09
AU2021261935B2 (en) 2023-10-19
JP2019519611A (ja) 2019-07-11
UA124672C2 (uk) 2021-10-27
AU2017282651A1 (en) 2018-12-06
AU2021261935A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
DK3436444T3 (da) Heterocyklisk forbindelse
DK3319956T3 (da) Substituerede oxopyridinderivater
BR112018002709A2 (pt) derivados heterobicíclicos microbicidas
DK3687999T3 (da) Rapamycinderivater
BR112017020349A2 (pt) derivados heterobicíclicos microbicidas
BR112017003168A2 (pt) derivados de heterocíclicos ativos do ponto de vista pesticida com substituintes contendo enxofre
BR112017002598A2 (pt) derivados heterocíclicos ativos do ponto de vista pesticida com substituintes contendo enxofre
BR112017012638A2 (pt) derivados de heterocíclicos ativos do ponto de vista pesticida com substituintes contendo enxofre
BR112017002407A2 (pt) derivados de heterocíclicos ativos do ponto de vista pesticida com substituintes contendo enxofre
MA47573A (fr) Inhibiteurs de dihydrobenzofurane glycosidase substitués
BR112017000269A2 (pt) derivados de heterocíclicos ativos do ponto de vista pesticida com substituintes contendo enxofre
BR112017003366A2 (pt) derivados de heterocíclicos ativos do ponto de vista pesticida com substituintes contendo enxofre
BR112016022043A2 (pt) derivados de heterocíclicos ativos do ponto de vista pesticida com substituintes contendo enxofre
BR112016022217A2 (pt) derivados de heterocíclicos ativos do ponto de vista pesticida com substituintes contendo enxofre
DK3642202T3 (da) Dihydro-pyrrolo-pyridin-derivater
DK3768669T3 (da) Piperazinazaspiroderivater
DK3371168T3 (da) Indolin-2-on-derivater
DK3652176T3 (da) Substituerede xanthinderivater
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
DK3368519T3 (da) Hidtil ukendte, heterocykliske antiøstrogener
DK3796975T3 (da) Sulfonylaminobenzamidderivater
DK3645513T3 (da) Benzazepinderivater
DK3894410T3 (da) Substituerede xanthinderivater
DK3450436T3 (da) Kondenseret heterocyklisk forbindelse